Mirum Pharmaceuticals Announces Positive Late-Stage Trial Results for Hepatitis D Drug Brelovitug
Mirum Pharmaceuticals (MIRM) has announced that its investigational antibody therapy, brelovitug, successfully met the primary endpoint in a second late-stage clinical trial. The drug is being developed for the treatment of chronic hepatitis delta virus. Following these successful results, the company plans to submit a regulatory filing to the U.S. Food and Drug Administration (FDA) early next year. This development marks a significant milestone in the clinical progression of brelovitug toward potential commercialization.
Tickers: $MIRM
Topics: clinical trial success FDA filing hepatitis delta virus
Read the full article at Seeking Alpha
Part of the story Johnson & Johnson Announces Positive Late-Stage Trial Results for Psoriatic Arthritis Treatment (3 articles)